Omeros (Omeros) 3-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)

View and export this data going back to 2009. Start your Free Trial

What is Omeros 3-Year Dividend Growth Rate?

Omeros's Dividends per Share for the three months ended in Dec. 2023 was $0.00.

The historical rank and industry rank for Omeros's 3-Year Dividend Growth Rate or its related term are showing as below:

OMER's 3-Year Dividend Growth Rate is not ranked ^*
in the Biotechnology industry.
Industry Median: 14.5
* Ranked among companies with meaningful 3-Year Dividend Growth Rate only.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Omeros's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, Omeros's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.

Competitive Comparison of Omeros's 3-Year Dividend Growth Rate

For the Biotechnology subindustry, Omeros's 3-Year Dividend Growth Rate, along with its competitors' market caps and 3-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Omeros's 3-Year Dividend Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Omeros's 3-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where Omeros's 3-Year Dividend Growth Rate falls into.

Omeros 3-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with expontential compound based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

Omeros (NAS:OMER) 3-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

Omeros's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.63
	=	N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Omeros 3-Year Dividend Growth Rate Related Terms>

Omeros (Omeros) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Omeros Corp (NAS:OMER) » Definitions » 3-Year Dividend Growth Rate

Comparable Companies

Traded in Other Exchanges

3O8:Germany

Address

201 Elliott Avenue West, Seattle, WA, USA, 98119

Website

https://www.omeros.com

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Executives

Demopulos Gregory A Md	director, 10 percent owner, officer: Chairman, CEO & President	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Demopulos Peter A Md	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Arnold C Hanish	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas J. Cable	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Diana T. Perkinson	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Michael A Jacobsen	officer: VP Finance and CAO	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Kurt Zumwalt	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Peter B Cancelmo	officer: See Remarks	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Thomas F. Bumol	director	201 ELLIOT AVENUE WEST, SEATTLE WA 98119
Marcia S. Kelbon	officer: VP Patent and General Counsel	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Ray Aspiri	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Hood Leroy E. Md Phd	director	201 ELLIOTT AVENUE WEST, SEATTLE WA 98119
Rajiv Shah	director	C/O ARCADIA BIOSCIENCES, INC., 202 COUSTEAU PLACE, SUITE 105, DAVIS CA 95618
Daniel K Spiegelman	director	MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Jean-philippe Tripet	director	1420 FIFTH AVENUE, SUITE 2600, SEATTLE WA 98101-2347